Clinical Trials Logo

Cerebral Amyloid Angiopathy clinical trials

View clinical trials related to Cerebral Amyloid Angiopathy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06421532 Not yet recruiting - Clinical trials for Cerebral Amyloid Angiopathy

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

Clear-Brain
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

A pre-post study will be conducted to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA. A total of 60 subjects, 30 with sCAA and 30 with D-CAA, will be randomly assigned to receive LXB, or both interventions. The primary outcome measure will be the morning levels of Aβ40 and Aβ42 in cerebrospinal fluid (CSF) before and after the intervention. The investigators will assess disease progression with (non-)haemorrhagic imaging markers on 7-Tesla Magnetic Resonance Imaging (7-T MRI) as a secondary outcome. Additionally, the activity of the glymphatic system by means of fluid dynamics will be assessed using 7-T MRI.

NCT ID: NCT04654026 Not yet recruiting - Clinical trials for Cerebral Amyloid Angiopathy

the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA

Start date: February 20, 2021
Phase:
Study type: Observational

Ischemic cardiovascular and cerebrovascular diseases are the main causes of death among people. Antiplatelet threrapy is very important for patients to prevent ischemic cardiovascular and cerebrovascular diseases.Ischemic cardiovascular patients of cerebral amyloid angiopathy (CAA) patients is as high as 20%, aspirin and clopidogrel is applied to prevent or treat the patient with CAA is controversial, there is no valid evidence of CAA crowd is safe to use of antiplatelet drugs, but progress in clinical treatment is usually based on patient condition for antiplatelet agents to prevent the occurrence of adverse events, such as blood clots.Therefore, this study is intended to be a single-center, prospective study of patients with ischemic cardiovascular and cerebrovascular diseases taking aspirin and clopidogrel, to determine whether the patients are combined with CAA , and to conduct a follow-up study for 12 months after team inclusion:1) The prevalence rate and gene spectrum of ischemic cardiovascular and cerebrovascular diseases among CAA patients enrolled in our hospital were analyzed;2) To explore the correlation between aspirin and clopidogrel drug genes and blood drug concentrations and diseases in patients with ischemic cardiovascular and cerebrovascular diseases complicated with CAA;3) To evaluate the efficacy and safety of aspirin and clopidogrel in patients with ischemic cardiovascular and cerebrovascular diseases who combined with CAA.

NCT ID: NCT02361411 Not yet recruiting - Clinical trials for Intracerebral Hemorrhage

Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy

Start date: February 2015
Phase: N/A
Study type: Observational

The purpose of this study is to 1. Early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools 2. get gene repertoire of Chinese 3. Build a cerebral amyloid angiopathy (CAA) prospective cohorts, observing the disease history, and exploring prognostic factors of hemorrhage in CAA patients